Cargando…

Efficacy and Safety of Carbon-Ion Radiotherapy for Stage I Non-Small Cell Lung Cancer with Coexisting Interstitial Lung Disease

SIMPLE SUMMARY: Interstitial lung disease (ILD) is a risk factor for lung cancer, but the treatment options are often limited because of concerns that ILD may worsen with treatment. In this study, we analyzed whether the presence or absence of ILD affects the outcome of carbon-ion radiotherapy (CIRT...

Descripción completa

Detalles Bibliográficos
Autores principales: Okano, Naoko, Kubo, Nobuteru, Yamaguchi, Koichi, Kouno, Shunichi, Miyasaka, Yuhei, Mizukami, Tatsuji, Shirai, Katsuyuki, Saitoh, Jun-ichi, Ebara, Takeshi, Kawamura, Hidemasa, Maeno, Toshitaka, Ohno, Tatsuya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8391416/
https://www.ncbi.nlm.nih.gov/pubmed/34439358
http://dx.doi.org/10.3390/cancers13164204
_version_ 1783743269601017856
author Okano, Naoko
Kubo, Nobuteru
Yamaguchi, Koichi
Kouno, Shunichi
Miyasaka, Yuhei
Mizukami, Tatsuji
Shirai, Katsuyuki
Saitoh, Jun-ichi
Ebara, Takeshi
Kawamura, Hidemasa
Maeno, Toshitaka
Ohno, Tatsuya
author_facet Okano, Naoko
Kubo, Nobuteru
Yamaguchi, Koichi
Kouno, Shunichi
Miyasaka, Yuhei
Mizukami, Tatsuji
Shirai, Katsuyuki
Saitoh, Jun-ichi
Ebara, Takeshi
Kawamura, Hidemasa
Maeno, Toshitaka
Ohno, Tatsuya
author_sort Okano, Naoko
collection PubMed
description SIMPLE SUMMARY: Interstitial lung disease (ILD) is a risk factor for lung cancer, but the treatment options are often limited because of concerns that ILD may worsen with treatment. In this study, we analyzed whether the presence or absence of ILD affects the outcome of carbon-ion radiotherapy (CIRT) for clinical stage I non-small cell lung cancer (NSCLC). For all cases, CT and clinical data were reviewed by a respiratory physician to determine the presence of ILD. Overall survival and disease-specific survival were lower in patients with ILD than in patients without ILD. There was no significant difference between the ILD group and the non-ILD group with respect to safety. CIRT was not associated with significantly more side-effects in patients with ILD than in patients without ILD. Coexisting ILD was a poor prognostic factor with respect to CIRT for clinical stage I lung cancer, as reported for other treatment methods. ABSTRACT: Interstitial lung disease (ILD) is a risk factor both for the development and treatment failure of lung cancer. In this retrospective study, we analyzed the outcome of carbon-ion radiotherapy (CIRT) in 124 patients with clinical stage I non-small cell lung cancer (NSCLC), of whom 26 (21%) had radiological signs of pre-existing ILD. ILD was diagnosed retrospectively by a pulmonologist based on critical review of CT-scans. Ninety-eight patients were assigned to the non-ILD group and 26 patients (21.0%) to the ILD group. There were significant differences in pre-treatment KL-6 values between the two groups. The three year overall survival and cause-specific survival rates were 83.2% and 90.7%, respectively, in the non-ILD group, and 59.7% and 59.7%, respectively, in the ILD group (between-group differences, p = 0.002 and p < 0.001). Radiation pneumonitis worse than Grade 2 was observed in three patients (3.0%) in the non-ILD group and two patients (7.6%) in the ILD group (p = 0.29). There were no cases of acute exacerbation in the ILD group. CIRT for stage I NSCLC was as safe in the ILD group as in the non-ILD group. Coexisting ILD was a poor prognostic factor in CIRT for clinical stage I lung cancer.
format Online
Article
Text
id pubmed-8391416
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-83914162021-08-28 Efficacy and Safety of Carbon-Ion Radiotherapy for Stage I Non-Small Cell Lung Cancer with Coexisting Interstitial Lung Disease Okano, Naoko Kubo, Nobuteru Yamaguchi, Koichi Kouno, Shunichi Miyasaka, Yuhei Mizukami, Tatsuji Shirai, Katsuyuki Saitoh, Jun-ichi Ebara, Takeshi Kawamura, Hidemasa Maeno, Toshitaka Ohno, Tatsuya Cancers (Basel) Article SIMPLE SUMMARY: Interstitial lung disease (ILD) is a risk factor for lung cancer, but the treatment options are often limited because of concerns that ILD may worsen with treatment. In this study, we analyzed whether the presence or absence of ILD affects the outcome of carbon-ion radiotherapy (CIRT) for clinical stage I non-small cell lung cancer (NSCLC). For all cases, CT and clinical data were reviewed by a respiratory physician to determine the presence of ILD. Overall survival and disease-specific survival were lower in patients with ILD than in patients without ILD. There was no significant difference between the ILD group and the non-ILD group with respect to safety. CIRT was not associated with significantly more side-effects in patients with ILD than in patients without ILD. Coexisting ILD was a poor prognostic factor with respect to CIRT for clinical stage I lung cancer, as reported for other treatment methods. ABSTRACT: Interstitial lung disease (ILD) is a risk factor both for the development and treatment failure of lung cancer. In this retrospective study, we analyzed the outcome of carbon-ion radiotherapy (CIRT) in 124 patients with clinical stage I non-small cell lung cancer (NSCLC), of whom 26 (21%) had radiological signs of pre-existing ILD. ILD was diagnosed retrospectively by a pulmonologist based on critical review of CT-scans. Ninety-eight patients were assigned to the non-ILD group and 26 patients (21.0%) to the ILD group. There were significant differences in pre-treatment KL-6 values between the two groups. The three year overall survival and cause-specific survival rates were 83.2% and 90.7%, respectively, in the non-ILD group, and 59.7% and 59.7%, respectively, in the ILD group (between-group differences, p = 0.002 and p < 0.001). Radiation pneumonitis worse than Grade 2 was observed in three patients (3.0%) in the non-ILD group and two patients (7.6%) in the ILD group (p = 0.29). There were no cases of acute exacerbation in the ILD group. CIRT for stage I NSCLC was as safe in the ILD group as in the non-ILD group. Coexisting ILD was a poor prognostic factor in CIRT for clinical stage I lung cancer. MDPI 2021-08-20 /pmc/articles/PMC8391416/ /pubmed/34439358 http://dx.doi.org/10.3390/cancers13164204 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Okano, Naoko
Kubo, Nobuteru
Yamaguchi, Koichi
Kouno, Shunichi
Miyasaka, Yuhei
Mizukami, Tatsuji
Shirai, Katsuyuki
Saitoh, Jun-ichi
Ebara, Takeshi
Kawamura, Hidemasa
Maeno, Toshitaka
Ohno, Tatsuya
Efficacy and Safety of Carbon-Ion Radiotherapy for Stage I Non-Small Cell Lung Cancer with Coexisting Interstitial Lung Disease
title Efficacy and Safety of Carbon-Ion Radiotherapy for Stage I Non-Small Cell Lung Cancer with Coexisting Interstitial Lung Disease
title_full Efficacy and Safety of Carbon-Ion Radiotherapy for Stage I Non-Small Cell Lung Cancer with Coexisting Interstitial Lung Disease
title_fullStr Efficacy and Safety of Carbon-Ion Radiotherapy for Stage I Non-Small Cell Lung Cancer with Coexisting Interstitial Lung Disease
title_full_unstemmed Efficacy and Safety of Carbon-Ion Radiotherapy for Stage I Non-Small Cell Lung Cancer with Coexisting Interstitial Lung Disease
title_short Efficacy and Safety of Carbon-Ion Radiotherapy for Stage I Non-Small Cell Lung Cancer with Coexisting Interstitial Lung Disease
title_sort efficacy and safety of carbon-ion radiotherapy for stage i non-small cell lung cancer with coexisting interstitial lung disease
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8391416/
https://www.ncbi.nlm.nih.gov/pubmed/34439358
http://dx.doi.org/10.3390/cancers13164204
work_keys_str_mv AT okanonaoko efficacyandsafetyofcarbonionradiotherapyforstageinonsmallcelllungcancerwithcoexistinginterstitiallungdisease
AT kubonobuteru efficacyandsafetyofcarbonionradiotherapyforstageinonsmallcelllungcancerwithcoexistinginterstitiallungdisease
AT yamaguchikoichi efficacyandsafetyofcarbonionradiotherapyforstageinonsmallcelllungcancerwithcoexistinginterstitiallungdisease
AT kounoshunichi efficacyandsafetyofcarbonionradiotherapyforstageinonsmallcelllungcancerwithcoexistinginterstitiallungdisease
AT miyasakayuhei efficacyandsafetyofcarbonionradiotherapyforstageinonsmallcelllungcancerwithcoexistinginterstitiallungdisease
AT mizukamitatsuji efficacyandsafetyofcarbonionradiotherapyforstageinonsmallcelllungcancerwithcoexistinginterstitiallungdisease
AT shiraikatsuyuki efficacyandsafetyofcarbonionradiotherapyforstageinonsmallcelllungcancerwithcoexistinginterstitiallungdisease
AT saitohjunichi efficacyandsafetyofcarbonionradiotherapyforstageinonsmallcelllungcancerwithcoexistinginterstitiallungdisease
AT ebaratakeshi efficacyandsafetyofcarbonionradiotherapyforstageinonsmallcelllungcancerwithcoexistinginterstitiallungdisease
AT kawamurahidemasa efficacyandsafetyofcarbonionradiotherapyforstageinonsmallcelllungcancerwithcoexistinginterstitiallungdisease
AT maenotoshitaka efficacyandsafetyofcarbonionradiotherapyforstageinonsmallcelllungcancerwithcoexistinginterstitiallungdisease
AT ohnotatsuya efficacyandsafetyofcarbonionradiotherapyforstageinonsmallcelllungcancerwithcoexistinginterstitiallungdisease